Status:
COMPLETED
Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)
Lead Sponsor:
Samsung Medical Center
Conditions:
Diabetic Retinopathy
Macular Edema
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
This study is designed to report 3-year result of triple therapy of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation for intractable diabetic macular edema. Previously author...
Eligibility Criteria
Inclusion
- clinical diagnosis of diabetes mellitus
- intractable diffuse DME (diffuse DME which did not respond to or recurred after the previous IVTA and/or macular focal laser photocoagulation)
- central subfield macular thickness (CST) greater than 250μm
Exclusion
- presence of vitreomacular traction
- a prior history of treatment for the DME within 3 months or vitreoretinal surgery
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2010
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT01202461
Start Date
August 1 2010
End Date
September 1 2010
Last Update
September 15 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, S. Korea, South Korea, 135-710